ArticleImmunotherapy advances2024

Pharmacokinetics, safety, and efficacy of 20% subcutaneous immunoglobulin (Ig20Gly) administered weekly or every 2 weeks in Japanese patients with primary immunodeficiency diseases: a phase 3, open-label study.

Hirokazu Kanegane et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.